MorphoSys (ETR:MOR) has been assigned a €129.00 ($150.00) price target by analysts at Deutsche Bank in a research report issued on Friday, Borsen Zeitung reports. The brokerage currently has a “buy” rating on the stock. Deutsche Bank’s price objective suggests a potential upside of 8.49% from the company’s previous close.
Several other research firms have also recently weighed in on MOR. Berenberg Bank set a €145.00 ($168.60) price objective on MorphoSys and gave the stock a “buy” rating in a report on Wednesday. Goldman Sachs Group set a €114.00 ($132.56) target price on MorphoSys and gave the company a “neutral” rating in a research note on Tuesday, November 19th. JPMorgan Chase & Co. set a €130.00 ($151.16) target price on MorphoSys and gave the company a “buy” rating in a report on Monday, November 18th. Independent Research set a €110.00 ($127.91) target price on MorphoSys and gave the company a “neutral” rating in a report on Friday, November 1st. Finally, HSBC set a €81.00 ($94.19) price target on shares of MorphoSys and gave the company a “sell” rating in a report on Friday, August 16th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of €119.86 ($139.37).
Shares of ETR:MOR opened at €118.90 ($138.26) on Friday. The stock’s 50-day moving average is €102.88 and its 200 day moving average is €99.16. The company has a market cap of $3.77 billion and a PE ratio of -39.09. The company has a debt-to-equity ratio of 9.78, a current ratio of 7.80 and a quick ratio of 7.63. MorphoSys has a 1 year low of €79.70 ($92.67) and a 1 year high of €114.70 ($133.37).
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Further Reading: Current Ratio
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.